Transition to tetraploidy in 1,25-dihydroxyvitamin D3-resistant HL60 cells is preceded by reduced growth factor dependence and constitutive Up-regulation of Sp1 and AP-1 transcription factors

Cancer Research

Volumn 56, Issue 23, 1996, Pages 5513-5521

  Studzinski, George P ^a   Rathod, Bina ^a   Rao, Jie ^a   Kheir, Ahmed ^a   Wajchman, Howard J ^a   Zhang, Fan ^a   Finan, Janet B ^b   Nowell, Peter C ^b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; GROWTH FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR SP1;

ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CELL GROWTH; CELL STRAIN HL 60; CONTROLLED STUDY; DNA BINDING; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; TETRAPLOIDY;

ANIMALS; CALCITRIOL; CATTLE; CELL DIFFERENTIATION; CELL DIVISION; CULTURE MEDIA; CULTURE MEDIA, SERUM-FREE; DISEASE PROGRESSION; DRUG RESISTANCE; GENE EXPRESSION REGULATION, LEUKEMIC; GROWTH SUBSTANCES; HL-60 CELLS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; POLYPLOIDY; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP-1;

EID: 0030480988     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Collins, S. J., Gallo, R. C., and Gallagher, R E. Continuous growth and differentiation of human myeloid leukemic cells in suspension cultures. Nature (Lond.), 270: 347-349, 1977.
2. Koeffler, H P., and Golde, D. W. Human myeloid leukemia cell lines: a review. Blood, 56: 344-350, 1980.
3. Chang, T. T., Gulati, S C., Chou, T. C , Vega, R., Gandola, L., Ezzat Ibrahim, S. M., Yopp, J., Colvin, M , and Clarkson, B. D. Synergistic effect of 4-hydroperoxycyclophosphamide and etoposide on a human promyelocytic leukemia cell line (HL-60) demonstrated by computer analysis. Cancer Res., 45: 2434-2439, 1985.
4. Collins, S. J. The HL-60 promyelocytic leukemia cell line proliferation, differentiation, and cellular oncogene expression. Blood, 70, 1233-1244, 1987.
5. Jena, S., Luo, X N., Beran, M., Kantarjian, H., and Atweh, G. F. Antisense RNA inhibition of phosphoprotein p18 expression abrogates the transformed phenotype of leukemia cells. Cancer Res., 56, 1445-1450, 1996.
6. Robertson, G. P., Coleman, A. B., and Lugo, T. G Mechanisms of human melanoma cell growth and tumor suppression by chromosome 6 Cancer Res., 56: 1635-1641, 1996.
7. Collins, S., and Groudine, M. Amplification of endogenous myc-related DNA sequences in a human myeloid leukaemia cell line. Nature (Lond.), 298, 679-681, 1982.
8. Dalla-Favera, R., Wong-Staal, F, and Gallo, R. C. Oncogene amplification in promyelocytic leukaemia cell line HL-60 and primary leukaemic cells of the same patient Nature (Lond.), 299: 61-63, 1982.
9. Murray, M. J , Cunningham, J. M., Parada, L. F , Dautry, F., Lebowitz, P., and Weinberg, R. A The HL-60 transforming sequence: a ras oncogene coexisting with altered myc genes in hematopoietic tumors Cell, 33. 749-757, 1993.
10. Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B , and Fornace, A. J., Jr A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71: 587-597, 1992
11. Wolf, D., and Rotter, V Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL60 cells. Proc Natl. Acad Sci. USA, 82: 790-794, 1985.
12. 3: in vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Res., 69, 1399-1407, 1985.
13. Studzinski, G. P., McLane, J. A., and Uskokovic, M. R. Signaling pathways for vitamin D-induced differentiation: implications for therapy of proliferative and neoplastic diseases. Crit. Rev. Eukaryotic Gene Exp., 3, 279-312, 1993.
14. 3. Cell Prolif., 27: 37-46, 1994.
15. 0 phase cell cycle block. Cell Prolif., 27: 643-654, 1994.
16. 3 in HL60 cells. Cancer Res., 56, 264-267, 1996.
17. 1 to S phase block in polyploid HL60 cells. J. Cell Physiol., 168: 18-25, 1996.
18. 3. Exp. Cell Res., 224: 312-322, 1996.
19. Nowell, P. C. The clonal evolution of tumor cell populations Science (Washington DC), 194: 23-28, 1976.
20. 3 correlates with reduced rate of maturation of DNA replication intermediates. Cancer Res., 51. 3451-3455, 1991
21. Bhalla, K., Nayak, R , and Grant, S. Isolation and characterization of deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-β-D-arabinofuranosylcytosine. Cancer Res., 44: 5029-5037, 1984.
22. 3 of a deoxycytidine kinase-deficient variant of human leukemia HL60 cells. Exp. Cell Res., 203: 244-250, 1992.
23. Studzinski, G. P., Gierthy, J. F., and Cholon, J. J. An autoradiographic screening test for mycoplasmal contamination of mammalian cell cultures. In Vitro, 8: 466-472, 1973.
24. Andrews, N. C., and Faller, D. V. Rapid micropreparation technique for extraction of DNA binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res., 19: 2499, 1991.
25. Wright, S D., Ramos, R. A., Tobias, S., Ulevitch, R J , and Mathison, J C. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science (Washington DC), 249: 1431-1433, 1990.
26. Griffin, J. D., Ritz, J., Nadler, L. M., and Schlossman, S. F. Expression of myeloid differentiation antigens on normal and malignant myeloid cells. J. Clin. Invest., 68: 932-941, 1981.
27. Griffin, J D., Mayer, R. J., Weinstein, H. J., Rosenthal, D. S., Coral, F. S., Beveridge, R. P., and Schlossman, S. F. Surface marker analysis of acute myeloblastic leukemia: identification of differentiation-associated phenotype. Blood, 62: 557-563, 1983.
28. Neri, A., and Nicolson, G L. Phenotypic drift of metastatic and cell surface properties of mammary adenocarcinoma cell clones during growth in vitro. Int. J. Cancer, 28: 731-738, 1981.
29. Nicolson, G. L. Tumor cell instability, diversification, and progression to the metastatic phenotype: from oncogene to oncofetal expression. Cancer Res , 47: 1473-1487, 1987
30. Holley, R. W , and Kierman, J. A Contact inhibition of cell division in 3T3 cells. Proc. Natl. Acad Sci USA, 60: 300-304, 1968.
31. Todaro, G J., and DeLarco, J E. Growth factors produced by sarcoma virus-transformed cells. Cancer Res., 38: 4147-4154, 1978.
32. Kadonaga, J. T., Carner, K. R., Masiarz, F R., and Tjian, R Isolation of cDNA encoding transcription factor Sp1 and analysis of the DNA binding domain. Cell, 51: 1079-1090, 1987.
33. Kolla, S. S., and Studzinski, G P. Constitutive DNA binding of the low mobility forms of the AP-1 and SP-1 transcription factors in HL60 cells resistant to arabinocytosine. Cancer Res., 54: 1418-1421, 1994.
34. 3. J. Cell Physiol , 156: 63-71, 1993.
35. Knudson, A. G., Jr. Heredity cancer, oncogenes, and antioncogenes. Cancer Res., 43: 1437-1443, 1983.
36. Sager, R. Genetic suppression of tumor formation: a new frontier in cancer research. Cancer Res , 46: 1573-2580, 1986.
37. Wyllie, A. H., Kerr, J. F. R., and Currie, A. R. Cell death: the significance of apoptosis In: G. H. Bourne, F. J. Danielli, and K. W. Jeon (eds.), International Review of Cytology, Vol 68. pp. 251-306. New York: Academic Press, 1992.
38. Studzinski, G. P. Oncogenes, growth, and the cell cycle: an overview. Cell Tissue Kinet., 22: 405-425, 1989.
39. Studzinski, G. P., Moore, D. C., and Carter, D. L. Suppressor genes: restraint of growth or of tumor progression? Lab. Invest , 63: 279-282, 1990
40. Ramachandra, S., and Studzinski, G. P. Morphological and biochemical criteria of apoptosis In: G. P. Studzinski (ed.), Cell Growth and Apoptosis: A Practical Approach, pp. 119-142. New York. Oxford University Press, 1995.
41. Nowell, P. C. Mechanisms of tumor progression. Cancer Res , 46: 2203-2207, 1986.
42. Fearon, E. R , and Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell, 61, 759-768, 1990.
43. Loeb, L. A Mutator phenotype may be required for multistage carcinogenesis. Cancer Res., 51: 3075-3083, 1991.
44. Kaufmann, W K , and Kaufman, D. G. Cell cycle control, DNA repair and initiation of carcinogenesis. FASEB J., 7: 1188-1191, 1993.
45. Liotta, L. A., and Stetler-Stevenson, W. G. Tumor invasion and metastasis: an imbalance of positive and negative regulation Cancer Res., 51(Suppl.): 5054s-5060s, 1991.
46. Jones, P. D., and Taylor, S. M. Cellular differentiation, cytidine analogs and DNA methylation. Cell, 2: 85-93, 1980.
47. Herman, J. G., Merlo, A., Mao, L., Lapidus, R. G., Issa, J. P. J., Davidson, N E., Sidransky, D., and Baylin, S. B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 55: 4525-4530, 1995.
48. Pascal, E., and Tjian, R. Different activation domains for Sp1 govern formation of multimers and mediate transcriptional synergism. Genes Dev., 5: 1646-1656, 1991.
49. 3. J. Immunol., 153: 3276-3284, 1994.